Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: Clinical effects and hematologic toxicity

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 3, 2003, Pages 317-325

  Robert, Francisco ^a,b,c   Busby, Elizabeth M ^a   LoBuglio, Albert F ^a  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antibody; Chemotherapy; Lung cancer; Radioimmunotherapy

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DOCETAXEL; EDETIC ACID; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IRINOTECAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49 Y 90; NAVELBINE; PACLITAXEL; PENTETIC ACID; PLATINUM DERIVATIVE; RECOMBINANT ALPHA2B INTERFERON; TOPOTECAN; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EVALUATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOSENSITIVITY; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 0043245045     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322285071     Document Type: Article

References (23)

1. 131I tositumomab for relapsed or refractory B-cell non-Hodgkin's lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259.
2. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM. Pivotal study of iodine I131 tosimmomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918.
3. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793.
4. Press OW, Eary JF, Appelbaum FR, Bernstein ID. Treatment of relapsed B cell lymphomas with high-dose radioimmunotherapy and bone marrow transplantation. In: Cancer Therapy with Radiolabeled Antibodies, Chapter 17, DM Goldenberg, CRC Press, Boca Raton, 1995, 229.
5. Breitz HB, Weiden PL, Beaumier PL. Radioimmunotherapy of solid tumors. In: Radioimmunotherapy of Cancer, PG Abrams, AR Fritzberg, Marcel Dekker, Inc, New York, 2000, 265.
6. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: Recent results and future directions. J Clin Oncol 1996;14:1383.
7. Meredith RF, LoBuglio AF, Spencer EB. Recent progress in radioimmunotherapy for cancer. Oncology 1997; 11:979.
8. TM (tositumomab and iodine I131 tositumomab) in patients with follicular lymphoma. Blood 2001;3, Abstract.
9. TM for non-Hodgkin's lymphoma. Blood 2001;98:604. Abstract.
10. 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer. Proc Am Assoc Cancer Res 2000;41:634. Abstract.
11. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994;35:1017.
12. Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J Nucl Med 1996;37:1491.
13. 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996;2:1811.
14. 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biotherapy Radiopharmaceut 1997;12:79.
15. 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. Clin Cancer Res 1999;5:3254s.
16. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin C-Y, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF. Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study. Cancer Biotherapy Radiopharmaceut 2001;16:305.
17. Press OW, Eary JF, Badger CC, Martin PJ, Appelbaum FR, Levy R, Miller R, Brown S, Nelp WB, Krohn KA, Fisher D, DeSantes K, Porter B, Kidd P, Thomas ED, Bernstein ID. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027.
18. 131I-M195/busulfan/cyclophosphamide (BU/Cy) in patients with advanced/refractory myeloid malignancies. Blood 1993; 82,Suppl:80. Abstract.
19. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117.
20. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987;5:407.
21. McLaughlin P, Hagemeister FB, Romaguera JE, Sarris AH, Pate O, Younes A, Swan F, Keating M, Cabanillas F. Fludarabine, mitoxantrone and dexamethasone: An effective new regimen for indolent lymphoma. J Clin Oncol 1996;14:1262.
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92.
23. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354.